Boston Partners trimmed its position in Labcorp Holdings Inc. (NYSE:LH – Free Report) by 3.4% during the third quarter, HoldingsChannel.com reports. The firm owned 2,948,535 shares of the medical research company’s stock after selling 103,155 shares during the quarter. Boston Partners’ holdings in Labcorp were worth $908,741,000 as of its most recent SEC filing.
A number of other institutional investors have also made changes to their positions in LH. Independent Advisor Alliance lifted its position in Labcorp by 24.9% during the 3rd quarter. Independent Advisor Alliance now owns 14,721 shares of the medical research company’s stock worth $4,590,000 after buying an additional 2,936 shares in the last quarter. Cibc World Market Inc. raised its holdings in Labcorp by 108.9% during the third quarter. Cibc World Market Inc. now owns 15,191 shares of the medical research company’s stock worth $4,680,000 after acquiring an additional 7,918 shares in the last quarter. Edgestream Partners L.P. bought a new stake in Labcorp during the third quarter worth about $1,006,000. Banco Santander S.A. acquired a new position in Labcorp during the third quarter valued at approximately $553,000. Finally, HighTower Advisors LLC boosted its position in Labcorp by 0.3% during the third quarter. HighTower Advisors LLC now owns 69,752 shares of the medical research company’s stock valued at $21,491,000 after purchasing an additional 184 shares during the last quarter. Institutional investors own 95.94% of the company’s stock.
Analysts Set New Price Targets
A number of brokerages have recently commented on LH. Deutsche Bank reissued a “hold” rating and issued a $355.00 price objective on shares of Labcorp in a research report on Thursday, October 29th. HSBC raised shares of Labcorp from a “hold” rating to a “buy” rating and set a $410.00 price target on the stock in a report on Thursday, November 5th. JPMorgan Chase & Co. raised their price objective on shares of Labcorp from $330.00 to $360.00 and gave the stock an “overweight” rating in a research report on Monday, August 3rd. Weiss Ratings upgraded Labcorp from a “buy (b+)” rating to a “buy (a-)” rating in a report on Wednesday, October 21st. Finally, Robert W. Baird upped their target price on Labcorp from $361.00 to $396.00 and gave the company an “outperform” rating in a research report on Thursday, October 29th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $369.08.
Insider Buying and Selling
In other Labcorp news, EVP Amy Summy sold 365 shares of the firm’s stock in a transaction on Monday, November 16th. The stock was sold at an average price of $372.58, for a total transaction of $135,991.70. Following the transaction, the executive vice president owned 6,590 shares in the company, valued at $2,455,302.20. This trade represents a 5.25% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Bryan Vaughn sold 306 shares of Labcorp stock in a transaction on Tuesday, November 3rd. The shares were sold at an average price of $353.70, for a total value of $108,232.20. Following the completion of the transaction, the executive vice president directly owned 6,845 shares of the company’s stock, valued at $2,421,076.50. This represents a 4.28% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 3,749 shares of company stock worth $1,377,699 in the last quarter. Insiders own 0.84% of the company’s stock.
Labcorp Price Performance
NYSE:LH opened at $370.68 on Thursday. Labcorp Holdings Inc. has a 52 week low of $245.00 and a 52 week high of $375.10. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.22 and a current ratio of 1.41. The firm’s 50-day simple moving average is $332.38 and its 200 day simple moving average is $294.09. The firm has a market cap of $30.10 billion, a price-to-earnings ratio of 20.36, a P/E/G ratio of 2.08 and a beta of 0.86.
Labcorp (NYSE:LH – Get Free Report) last announced its earnings results on Wednesday, October 28th. The medical research company reported $4.78 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.64 by $0.14. Labcorp had a net margin of 6.88% and a return on equity of 17.13%. The firm had revenue of $3.81 billion for the quarter, compared to analyst estimates of $3.76 billion. During the same quarter in the prior year, the business posted $4.18 EPS. The business’s revenue was up 6.9% compared to the same quarter last year. As a group, sell-side analysts predict that Labcorp Holdings Inc. will post 18.51 earnings per share for the current year.
Labcorp Dividend Announcement
The business also recently declared a quarterly dividend, which will be paid on Friday, December 11th. Investors of record on Tuesday, November 24th will be given a dividend of $0.72 per share. The ex-dividend date of this dividend is Tuesday, November 24th. This represents a $2.88 dividend on an annualized basis and a yield of 0.8%. Labcorp’s dividend payout ratio is currently 23.63%.
About Labcorp
Labcorp (NYSE: LH), formally Laboratory Corporation of America Holdings, is a global life sciences company that provides diagnostic testing and services to patients, physicians, hospitals, employers and other health care organizations. Its offerings include routine and specialty laboratory tests, anatomic pathology and genetic testing. The company also supports pharmaceutical and biotechnology companies with laboratory services for drug development and clinical trials, including testing and analysis used in research and clinical studies.
See Also
- Five stocks we like better than Labcorp
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Want to see what other hedge funds are holding LH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Labcorp Holdings Inc. (NYSE:LH – Free Report).
Receive News & Ratings for Labcorp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Labcorp and related companies with MarketBeat.com's FREE daily email newsletter.
